Dow divests stake in composite joint venture to Aksa Akrilik

Dow Chemical (DOW) will sell its 50% stake in DowAksa Advanced Composites to joint venture partner Aksa Akrilik for $125 million, reflecting 10x estimated 2025 operating EBITDA; the sale aligns with Dow's strategy to focus on core downstream businesses and improve financial flexibility amid a significant debt burden. This divestiture is part of a broader capital allocation strategy aimed at balanced growth and shareholder returns, even as the company faces challenges including a recent EPS miss and a revised price target from Barclays, which maintains an Equalweight rating.

Analysis

Dow Chemical (DOW), with reported 2024 sales of approximately $43 billion, is divesting its 50% stake in the DowAksa Advanced Composites joint venture to its partner, Aksa Akrilik Kimya Sanayii A.Ş., for $125 million. This transaction, valued at approximately 10 times the joint venture's estimated 2025 operating EBITDA and expected to close in Q3 2025, aligns with Dow's strategy to concentrate on its core, high-value downstream businesses and enhance financial flexibility. This strategic shift is pertinent given Dow's significant debt burden, reflected in a debt-to-equity ratio of 1.07, and a gross profit margin of 9.56%. Despite a substantial 34.75% stock price decline over the past six months, InvestingPro data suggests potential undervaluation, while the company offers a notable 10.09% dividend yield. Dow's recent Q1 2025 earnings presented a mixed picture, with an EPS miss at $0.02 against an expected $0.03, though revenues of $10.4 billion slightly exceeded the $10.28 billion anticipated. To address these challenges and global demand headwinds, particularly in Europe and China, Dow is implementing cost reductions targeting $1 billion by 2026, delaying capital expenditures, and pursuing further asset sales, including strategic infrastructure transactions expected to yield $2.4 billion in cash by May 1 and a recently approved deal with Macquarie Asset Management. Reflecting cautious sentiment, Barclays revised Dow's price target downwards to $32 from $38, maintaining an Equalweight rating due to concerns about earnings stability.

Key Decisions for Investors

• Investors should consider the DowAksa divestiture's positive impact on deleveraging and strategic focus, but weigh this against the existing high debt levels and recent earnings volatility before making investment decisions.
• It is prudent to monitor the progress of announced asset sales, such as the $2.4 billion expected from infrastructure transactions, and the execution of the $1 billion cost reduction program for tangible improvements to Dow's financial flexibility and profitability.
• The attractive 10.09% dividend yield should be assessed in conjunction with the stock's significant recent underperformance, ongoing operational challenges, and the cautious analyst outlook, indicating a need for careful risk evaluation.